Startups
Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays.
SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE's immunoassays. The short epitope allows us to establish quantitative assays for the same protein in different species and for isoforms of protein families. Even immunoassays for notoriously difficult proteins like drug transporters can be established while providing the speed and the sensitivity of an antibody-based method.
SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE's immunoassays. The short epitope allows us to establish quantitative assays for the same protein in different species and for isoforms of protein families. Even immunoassays for notoriously difficult proteins like drug transporters can be established while providing the speed and the sensitivity of an antibody-based method.
Overview
Location
Germany, Baden-Württemberg, Reutlingen
Employees
11-50
Total raised
$670.95K
Founded date
2016
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 1
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
Reviews 0
FAQ about Signatope
When was Signatope founded?
Signatope was founded in 2016.
How much funding has Signatope raised?
Signatope has raised $670.95K in total across 1 funding round.
Is Signatope still active?
Signatope is probably closed: its latest activity on Parsers VC dates from May 26, 2017.